What are the risk factors associated with peptic ulcer disease?

(Select All that Apply.)

A) H2-receptor blockers:
H2-receptor blockers, such as ranitidine and famotidine, are used to reduce the production of stomach acid. While they can provide symptomatic relief for ulcers by reducing acid secretion, they do not directly treat the underlying cause of the ulcer, which is the H. pylori infection.

B) Antacids:
Antacids are medications that neutralize stomach acid and can provide temporary relief from ulcer symptoms such as pain and discomfort. However, they do not eradicate the H. pylori bacteria or address the root cause of the ulcer. Antacids only provide symptomatic relief rather than treating the infection.

C) Proton-pump inhibitors:
Proton-pump inhibitors (PPIs), such as omeprazole and pantoprazole, are potent acid-suppressing medications that are commonly used to treat ulcers and gastroesophageal reflux disease (GERD). While they can help in ulcer healing by reducing acid secretion and providing symptomatic relief, they are not effective in eradicating H. pylori infection. PPIs are often used in combination with antibiotics for H. pylori eradication therapy, but they are not the primary treatment on their own.

D) Antibiotics.
H. pylori (Helicobacter pylori) is a bacteria that commonly infects the stomach lining and is a major cause of gastric and duodenal ulcers. Antibiotics are the primary treatment for H. pylori infection. The antibiotics kill the bacteria, allowing the ulcer to heal. Common antibiotics used to treat H. pylori include amoxicillin, clarithromycin, metronidazole, and tetracycline.

A. Decreased cardiac output: Inotropic medications are intended to improve cardiac function and increase cardiac output, so monitoring for signs of decreased cardiac output would be contrary to the expected therapeutic effect of these medications.

B. Increased afterload: Inotropic medications primarily affect the contractility of the heart muscle and do not typically have a direct effect on afterload (the force against which the heart must pump blood). While changes in afterload can occur as a secondary consequence of altered cardiac function, monitoring for signs of increased afterload would not be the primary focus after administering an inotropic medication.

C. Increased cardiac output.
Inotropic medications are drugs that affect the contractility of the heart muscle. They are often used in the management of shock to improve cardiac function and increase cardiac output. Therefore, after administering an inotropic medication, the nurse would monitor the patient for signs of increased cardiac output, such as improved peripheral perfusion, increased blood pressure, and resolution of signs and symptoms of shock.

D. Slowing of the heart rate: Inotropic medications can affect heart rate indirectly by altering cardiac output, but their primary effect is on contractility rather than heart rate. Monitoring for signs of bradycardia (slowing of the heart rate) may be appropriate in certain clinical situations, but it is not the primary consideration after administering an inotropic medication for shock.